4-Chlorophenylisobutylamine
This is an old revision of this page, as edited by Rjwilmsi (talk | contribs) at 14:57, 29 January 2016 (→top: Journal cites: format journal names, using AWB (11852)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H14ClN |
Molar mass | 183.68 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
4-Chlorophenylisobutylamine (4-CAB, AEPCA), also known as 4-chloro-α-ethylphenethylamine, is an entactogen and stimulant drug of the phenethylamine class.[1] It is an analogue of para-chloroamphetamine (PCA) where the alpha position methyl has been replaced with an ethyl group.[1]
In comparison to PCA, 4-CAB is approximately 2- and 5-fold less potent at inhibiting the reuptake of serotonin (IC50 = 330 nM) and dopamine (IC50 = 2,343 nM), respectively, and is about 3-fold less potent in substituting for MDMA in animals in drug discrimination assays.[1] Though its dopaminergic activity is significantly attenuated compared to PCA, unlike the case of MBDB, it is not abolished, and is actually similar to that of MDMA.[1]
Relative to PCA, 4-CAB is also substantially less effective as a serotonergic neurotoxin.[1] A single 10 mg/kg administration of PCA to rats produces an approximate 80% decrease in serotonin markers as observed 1 week later.[1] In contrast, 11 mg/kg and 22 mg/kg doses of 4-CAB result in only 20% and 50% decreases, respectively.[1] This is once again similar to MDMA which causes a 40-60% reduction with a single 20 mg/kg dose.[2]
See also
References
- ^ a b c d e f g Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE (November 1990). "Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine". European Journal of Pharmacology. 191 (1): 1–10. doi:10.1016/0014-2999(90)94090-K. PMID 1982656.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Aguirre N, Barrionuevo M, Ramírez MJ, Del Río J, Lasheras B (November 1999). "Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity". NeuroReport. 10 (17): 3675–80. doi:10.1097/00001756-199911260-00039. PMID 10619665.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)
Phenylalkyl- amines (other than cathinones) |
|
---|---|
Cyclized phenyl- alkylamines | |
Cathinones | |
Tryptamines | |
Chemical classes |
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
- CS1 maint: multiple names: authors list
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Chem-molar-mass both hardcoded and calculated
- Infobox-drug molecular-weight unexpected-character
- Pages using infobox drug with unknown parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes which contain changes to verified fields